Clinical Strategy / Launch Excellence
A risk-weighted framework for assessing pharmaceutical launch readiness, grounded in empirical failure data from industry benchmarking studies. Seven dimensions — weighted by how often each factor causes launch failure — produce an actionable diagnostic that goes beyond activity checklists to identify where a launch is most likely to break.
The interactive case study models a pre-commercial biotech (~100 employees) launching an oral erythropoiesis modifier for lower-risk MDS with ring sideroblasts against Reblozyl (luspatercept, BMS) — a scenario that highlights the tension between genuine clinical differentiation and the execution risk of competing against an entrenched franchise.
Disclaimer: This is a proof-of-concept demonstration using a hypothetical scenario. All clinical data, market assumptions, and competitive intelligence are illustrative and based on publicly available information. This tool does not represent the actual strategy, pipeline data, or commercial plans of any specific company. It is not intended as investment advice or clinical guidance.
of launches that disappoint in Year 1 never recover their projected trajectory
ZS Associates, Launch Excellence Benchmarking, 2023of disappointing launches cite poor clinical differentiation as the primary cause
ZS Associates, 2023of underperforming launches cite inadequate market understanding as a root cause
McKinsey, 2024Most pharmaceutical companies use activity-based launch planning: field force hired, speaker bureau built, AMCP dossier filed. Each milestone gets a checkbox. The problem is that activity completion does not equal readiness. You can check every box and still fail.
This framework takes a fundamentally different approach. Instead of asking "did we do the activities?", it asks "where are we most likely to fail, and how severe is each risk?"
The 7 dimensions below are weighted by empirical failure data drawn from published launch analyses and industry benchmarks — not equal weights, not gut feel. The result is a risk-based readiness score that concentrates attention where it matters most: on the dimensions that actually predict launch success or failure.
The seven dimensions below are not equally weighted. Each weight reflects the empirical contribution of that dimension to launch outcomes, drawn from published failure analyses and industry benchmarks. Clinical differentiation and market intelligence together account for 43% of the total score because the data shows they are the two strongest predictors of first-year performance.
Evaluates the strength, maturity, and defensibility of the clinical evidence package relative to the competitive standard of care. Includes both efficacy differentiation and the vulnerability of cross-trial comparisons.
58% of disappointing launches cite poor clinical differentiation as the primary cause.
ZS Associates, Launch Excellence Benchmarking, 2023Benchmark: Products with head-to-head superiority data achieve 2.4x faster peak share vs cross-trial narratives.
ZS Associates, Launch Excellence Benchmarking, 2023Assesses the depth and actionability of competitive intelligence, the realism of resource asymmetry assessment, and the understanding of incumbent switching dynamics.
56% of underperforming launches cite inadequate market understanding as a root cause.
McKinsey & Company, "Getting the Launch Right," 2024Benchmark: Launches with dedicated CI functions achieve 31% higher first-year revenue vs those without systematic competitor tracking.
McKinsey & Company, "Getting the Launch Right," 2024Evaluates reimbursement pathway clarity, pricing strategy defensibility, and the complexity of channel dynamics that will determine real-world patient access.
65% of specialty drugs face significant access barriers within the first 6 months of launch.
Trinity Life Sciences, Market Access Barriers Report, 2023Benchmark: Day-1 formulary access at top 20 payers correlates with 40% higher launch trajectory vs 6-month access delays.
Trinity Life Sciences, Market Access Barriers Report, 2023Assesses the readiness of sales force, distribution infrastructure, hub services, and digital capabilities required to execute a successful commercial launch.
Pre-commercial biotechs have 35-40% lower first-year launch performance vs established commercial organizations.
McKinsey & Company, Pharma Launch Benchmarking, 2023Benchmark: Field force deployment 6+ months pre-launch correlates with 2x higher Day-1 share vs post-approval hiring.
McKinsey & Company, Pharma Launch Benchmarking, 2023Evaluates the depth of key opinion leader relationships, MSL deployment readiness, and the maturity of the publication and congress strategy.
73% of HCPs cite peer influence as a top-3 factor in adopting a new treatment.
McKinsey & Company, HCP Decision-Making Survey, 2023Benchmark: Products endorsed by 5+ Tier 1 KOLs at launch achieve 45% faster adoption curves in the first 12 months.
McKinsey & Company, HCP Decision-Making Survey, 2023Evaluates patient identification infrastructure, market penetration dynamics, and the readiness of patient support and adherence programs.
In rare diseases, the median time from symptom onset to accurate diagnosis exceeds 5 years.
National Organization for Rare Disorders (NORD), 2023Benchmark: Products with proactive patient identification programs achieve 25% higher diagnosed prevalence within 2 years of launch.
Author analysis of published launch outcomes dataEvaluates leadership experience, cross-functional governance maturity, and the availability of partnership or acquisition options that can de-risk the launch.
80% of launches that disappoint in Year 1 never recover their projected trajectory.
Deloitte, Pharma Launch Performance Study, 2023Benchmark: Companies with formal launch governance structures (clear decision rights, milestone gates) are 2.1x more likely to meet Year 1 targets.
Deloitte, Pharma Launch Performance Study, 2023Evaluates the strength, maturity, and defensibility of the clinical evidence package relative to the competitive standard of care. Includes both efficacy differentiation and the vulnerability of cross-trial comparisons.
Efficacy is the single strongest driver of prescriber adoption. Head-to-head data eliminates ambiguity; cross-trial comparisons are inherently vulnerable to methodological challenge.
Prescribers in rare disease require confidence in treatment durability. Incumbents with 3+ years of follow-up data have a structural advantage that can only be overcome with time.
Safety differentiation drives switching behavior even when efficacy is comparable. A meaningfully better AE profile can compensate for modest efficacy differences.
Without head-to-head data, cross-trial comparisons become the primary evidence for differentiation. Differences in trial design, patient populations, or endpoints create exploitable vulnerabilities for competitors.
Assesses the depth and actionability of competitive intelligence, the realism of resource asymmetry assessment, and the understanding of incumbent switching dynamics.
The incumbent will not stand still. Understanding their defensive playbook — pricing responses, counter-detailing strategy, lifecycle data generation — is as important as understanding their clinical data.
Pre-commercial biotechs systematically underestimate the resource advantage of established competitors. A 100-person company cannot out-detail a 30,000-person franchise on field presence alone.
Patients stable on an existing therapy rarely switch. The addressable market for a second entrant is primarily new patient starts, treatment failures, and intolerant patients — not the incumbent's installed base.
Evaluates reimbursement pathway clarity, pricing strategy defensibility, and the complexity of channel dynamics that will determine real-world patient access.
Orphan Drug designation, breakthrough therapy status, and first-in-class positioning all create structural reimbursement advantages. Second-in-class products face formulary positioning challenges regardless of clinical merit.
AMCP-compliant dossiers with published pharmacoeconomic evidence accelerate formulary review. Without HEOR data, pricing is vulnerable to payer challenge.
The Part B (physician-administered) vs Part D (pharmacy benefit) distinction creates fundamentally different economic incentives for prescribers, payers, and patients.
Assesses the readiness of sales force, distribution infrastructure, hub services, and digital capabilities required to execute a successful commercial launch.
Building a sales force takes 12-18 months from recruitment through training to territory deployment. Every month of delay post-approval represents permanently lost share.
In specialty pharmacy, the hub IS the commercial product. Prior authorization support, copay assistance, adherence programs, and patient onboarding all flow through hub services.
For a pre-commercial biotech, digital is not a "nice to have" — it is the force multiplier that compensates for smaller field presence vs an established competitor.
Evaluates the depth of key opinion leader relationships, MSL deployment readiness, and the maturity of the publication and congress strategy.
In rare diseases, a small number of thought leaders disproportionately influence prescribing behavior. Their advocacy — or lack thereof — can make or break a launch.
MSLs build the scientific foundation that precedes commercial launch. In rare disease, MSL-KOL relationships often determine whether a product is discussed at tumor boards and treatment guidelines committees.
Clinical data must be disseminated through the channels that prescribers trust: peer-reviewed publications, congress presentations, and post-hoc analyses. Regulatory filings alone are insufficient.
Evaluates patient identification infrastructure, market penetration dynamics, and the readiness of patient support and adherence programs.
In rare disease, the biggest competitor is often not the incumbent drug — it is underdiagnosis. Claims-based algorithms, genetic testing partnerships, and disease education can expand the diagnosed population.
Low class penetration means the opportunity is in growing the treated population, not capturing share from the incumbent. High penetration means the battle is zero-sum.
In specialty pharmacy, the patient experience IS the product. Copay assistance, adherence support, nurse navigators, and financial counseling determine whether a prescription converts to a fill and whether patients persist on therapy.
Evaluates leadership experience, cross-functional governance maturity, and the availability of partnership or acquisition options that can de-risk the launch.
Launch execution is a skill developed through experience. First-time commercial teams systematically underestimate the complexity of launch logistics, market access negotiations, and field force management.
A launch is not a regulatory event — it is a cross-functional execution challenge requiring coordinated decision-making across medical, commercial, regulatory, manufacturing, and market access.
For a pre-commercial biotech, the decision to launch independently vs partnering or being acquired is itself a strategic choice. Partnership can provide commercial infrastructure; acquisition provides certainty.
A pre-commercial biotech with ~$350M in cash is preparing to launch an oral small-molecule targeting ineffective erythropoiesis in SF3B1-mutant lower-risk MDS. The primary competitor is Reblozyl (luspatercept-aamt, BMS), a first-in-class erythroid maturation agent administered as a subcutaneous injection every 3 weeks, with ~$1.2B in annual revenue and BMS's full hematology franchise infrastructure behind it.
Oral Convenience Does Not Equal Clinical Superiority
The Phase 3 transfusion independence rate of 42% vs Reblozyl's 38% in MEDALIST is directionally favorable but not statistically differentiated. Without head-to-head data, this is a convenience play — not a clinical advance. BMS will aggressively frame the narrative as "comparable efficacy in a less-proven formulation" and leverage 3+ years of MEDALIST and COMMANDS durability data against a product with topline results only.
The GI toxicity profile (diarrhea ~35%, nausea ~28%) introduces a new adverse event burden that Reblozyl does not carry. In an elderly population (median age ~70) already managing comorbidities, GI intolerance may drive early discontinuation, undermining the oral convenience narrative.
BMS Does Not Just Own Reblozyl — It Owns the MDS Ecosystem
Reblozyl exists within BMS's hematology franchise: Revlimid (legacy relationships), Onureg (hypomethylating agent), and Reblozyl create a portfolio effect. BMS reps call on MDS-treating hematologists for 3+ products. A pre-commercial challenger with 1 product and 40-50 reps cannot match the frequency, depth, or breadth of BMS's account coverage. The competitive battle is not product vs product — it is franchise vs startup.
BMS's counter-detailing strategy will exploit the cross-trial comparison vulnerability: different patient populations (SF3B1-enriched vs broader LR-MDS), different endpoints definitions, and different assessment timepoints. Expect a MAIC rebuttal within 6 months of your first congress presentation.
The Part B vs Part D Paradox
Reblozyl is physician-administered (Part B, buy-and-bill). Community oncologists earn a margin on Reblozyl administration. An oral product (Part D, pharmacy benefit) removes that revenue stream — creating a financial incentive for community practices to maintain Reblozyl prescribing. Academic centers, which typically don't profit from buy-and-bill, are more receptive to oral therapy but treat a smaller share of MDS patients.
Medicare Part D specialty tier copays for oral oncology drugs average $7,000-10,000/year before catastrophic coverage. For MDS patients (median age ~70, often on fixed incomes), this creates an affordability crisis that injectable Reblozyl — covered under Part B with predictable 20% coinsurance — does not face. Without an aggressive copay assistance program, access on paper does not translate to access in practice.
100 People vs a Franchise
The math is unforgiving. BMS has dedicated hematology/oncology sales teams that have called on MDS-treating hematologists for years — first with Revlimid, now with Reblozyl and Onureg. Building a 40-50 person field force from a 100-employee base requires recruiting, training, and deploying in ~12-18 months while simultaneously managing NDA submission, advisory committees, and hub buildout.
The ~3,000 hematologists who treat MDS are distributed across both academic centers and community oncology practices. An oral therapy shifts the prescribing channel from community oncology (where reps have limited access but volume is high) to retail/specialty pharmacy. This creates a distribution channel challenge that few pre-commercial biotechs have navigated at scale.
The MDS Community Is Small, and BMS Already Lives There
MDS is a tight-knit academic community. The MDS Foundation, ASH's MDS Working Group, and ~50 thought leaders at major academic centers drive treatment guidelines and adoption. Trial PIs serve as natural advocates, and ASH/EHA congress presentations establish scientific credibility. However, BMS has multi-year advisory board relationships with the majority of these KOLs.
MDS KOLs who serve as investigators on your Phase 3 trial may have existing consulting agreements with BMS for Reblozyl or Onureg. The conflict disclosure landscape in hematology means your most natural advocates may face real or perceived conflicts that limit their willingness to publicly champion a BMS competitor.
500,000 Anemia Patients, 20,000 MDS Diagnoses — The Identification Gap
MDS is systematically underdiagnosed, particularly in community settings where anemia in elderly patients is attributed to iron deficiency, chronic disease, or "aging." Bone marrow biopsy — the gold standard for MDS diagnosis — is an invasive procedure that many community hematologists defer. ICD-10 D46.x coding exists but is under-utilized.
Low Reblozyl class penetration (<30% of eligible RS+ patients) means the opportunity is in growing the treated population, not switching. But this also means the biggest barrier to your launch is not BMS — it is the diagnostic inertia that keeps eligible patients on ESAs or transfusion support instead of targeted therapy. Disease education investment may benefit the entire class, including Reblozyl.
The Pre-Commercial Scaling Problem
Scaling from 100 to 300+ employees in 18 months to support a commercial launch — while simultaneously managing NDA filing, FDA advisory committee preparation, AMCP dossier development, hub services build, and field force recruitment — is an organizational challenge that breaks companies without established governance. The CEO's prior hematology launch experience provides strategic credibility, but institutional processes must be built.
The acquisition optionality (attractive target for BMS, AbbVie, or J&J given the differentiated oral MDS asset) creates a strategic tension. Is the company building to launch, or building to be acquired? If the answer is "both," the dual-track strategy can dilute focus and create organizational uncertainty that slows execution during the critical pre-launch window.
Overall Score: 40/100 — Not Ready. This product has a genuine clinical differentiator (oral dosing in an elderly population) and a validated mechanism in a genetically defined subgroup. However, the pre-commercial execution risk, BMS's entrenched franchise, and Part B vs Part D economics create significant headwinds that require aggressive mitigation in the 18-24 months before projected launch.
Prioritized commercial action plan for the lower-risk MDS oral erythropoiesis modifier launch against Reblozyl. Items are scored by their criticality to launch trajectory — not by organizational ownership or effort level. Critical Path items, if delayed or missed, permanently impair launch performance and rarely recover. High Impact items materially accelerate trajectory when executed well.
Stand up Phase 3 PI-based advisory board — 20-25 Tier 1 MDS KOLs before BMS counter-engages post-COMMANDS OLE readout
Trial investigators are natural advocates. Once BMS begins post-OLE counter-detailing, KOL access narrows rapidly. Every month of delay is access permanently ceded.
Commission MAIC vs Reblozyl using SF3B1-enriched cohort — own the methodology before BMS publishes their own version
BMS will produce a competing MAIC within 6 months of your first congress presentation. The party that files first controls the patient selection assumptions and statistical framing.
Hire CCO, VP Market Access, and VP Medical Affairs before building any field force
A sales force without commercial leadership is strategically adrift. These three roles define the entire launch architecture — without them, headcount decisions, territory mapping, and hub design are all made ad hoc.
Submit Phase 3 full manuscript to NEJM or Blood — target publication 8-10 months before NDA filing
The landmark publication sets the scientific narrative before BMS can produce an effective rebuttal. NEJM publication reaches a broader prescriber audience than a regulatory filing and establishes credibility with community hematologists who will not read an NDA.
Initiate pre-submission dialogue with top 5 PBM formulary teams (CVS Caremark, ESI, OptumRx, Prime, Anthem)
PBMs evaluate value evidence 12-18 months before approval. Starting conversations now shapes their analytical framework before they read BMS's dossier first. Late engagement results in unfavorable formulary positioning that persists for 12-24 months post-launch.
Launch NPI-gated unbranded disease education hub: "MDS and Erythropoiesis" — OPDP-compliant, accessible to MSLs as leave-behind content
Establishing scientific credibility in the unbranded space before promotion begins. A portal with 2,000+ NPI-authenticated HCP registrations at NDA filing provides a first-party data asset that cannot be replicated after brand activation begins.
Build total cost of care economic model: oral therapy vs infusion center visits, chair time, travel, and nursing burden
The Part D oral copay paradox is a structural access barrier. Proactively quantifying the total cost offset — infusion center visits, nursing time, transportation — gives payers a cost-neutral framing before their own actuarial teams frame it adversely.
For a pre-commercial biotech with 40-50 field reps competing against a BMS franchise, digital is not a supplemental channel — it is the force multiplier that compensates for the field presence gap. The objective is NPI-level precision: every digital touch is traceable to a specific prescriber, a specific moment in their journey, and a specific downstream Rx outcome via Crossix attribution.
The MDS prescriber universe is tight and measurable: ~3,000 hematologists across academic and community settings, 85 Centers of Excellence, and a disease defined enough (ICD-10 D46.x, SF3B1 testing codes) to support real-time claims-based triggering. This is one of the most targetable rare disease launches in hematology.
A synchronized sequence across medical, field, and digital channels. The goal is not touchpoint volume — it is orchestrated sequence: each touchpoint sets context for the next, so the rep call lands on a prescriber who already understands the mechanism.
Sequencing principle: Digital pre-conditions the field call. Rep pre-conditions the digital follow-up. The MSL builds the scientific credibility that makes the brand impression land. Attribution closes the loop so budget allocations reflect Rx outcomes, not impressions.
Tactic
Disease education pre-brand ("Understanding SF3B1-mutant MDS") → approval announcement → branded "Deep Response" creative with Phase 3 waterfall plots
Timing
T-18mo unbranded → Day 1 branded
HCP Targeting
NPI-list upload (~3,000 verified hematologists); specialty filter + ICD-10 usage pattern
Primary KPI
Unique HCP reach; Doximity read rate (benchmark: 35-45%)
Secondary KPI
HCP portal click-through; Crossix Rx lift in exposed vs unexposed cohort
Tactic
"MDS in 2026: Optimizing Response in SF3B1+ Patients" CME module pre-brand (target: 1,500 HCP completions); branded leaderboard + interstitial display at launch with Phase 3 clinical data creative
Timing
T-6mo (unbranded CME) → Day 1 (branded display)
HCP Targeting
Hematology specialty filter + MDS/AML editorial context adjacency targeting
Primary KPI
CME completions pre-brand; post-exposure brand recall survey (target: >30% aided recall)
Secondary KPI
Crossix Rx attribution in CME completers vs matched non-completers
Tactic
Unbranded search capture pre-NDA driving HCPs to SF3B1 testing pathway content; branded at approval routing to MDS Precision Hub NPI enrollment
Timing
NDA filing (unbranded) → Day 1 (branded)
HCP Targeting
Keywords: "lower risk MDS treatment," "SF3B1 mutation MDS," "luspatercept alternative," "[brand name] MDS"
Primary KPI
Search impression share vs Reblozyl SEM activity (target: >35%)
Secondary KPI
HCP portal sign-up rate per paid click
Tactic
D46.x claim detected → 24-hr rep notification in Veeva CRM → synchronized Doximity message to same NPI → hub enrollment prompt in next rep interaction
Timing
Launch day onward (operationalize 6 weeks pre-approval)
HCP Targeting
HCPs filing ICD-10 D46.x (MDS) codes within previous 30 days → real-time alert to territory rep
Primary KPI
Trigger-to-first-contact latency (target: <24 hrs); trigger-attributed Rx conversion rate
Secondary KPI
Triggered vs non-triggered HCP time-to-first-Rx comparison
Tactic
30-day synchronized sequence: Day 0 rep call → Day 3 clinical summary email → Day 14 branded eDetail → Day 30 "MDS Precision in Practice" case study → Day 45 congress data recap
Timing
Launch (post first rep call enrollment)
HCP Targeting
Permission-based NPI list; rep call → CRM trigger → approved email sequence auto-sends within compliance window
Primary KPI
Open rate (benchmark: >28% in oncology specialty email); sequence completion rate
Secondary KPI
Rep + digital multi-touch attribution to Rx activity via Crossix
Tactic
6 programs/year, 60-min KOL-led CME: MDS case presentation + Phase 3 data review + live Q&A. Target 150-200 HCPs/event = 900-1,200 unique peer-to-peer touches annually. Record for on-demand access.
Timing
T-3mo (speaker training) → ongoing post-launch
HCP Targeting
Invitation via rep CRM trigger + Doximity invitation to broader NPI list beyond rep reach
Primary KPI
Attendance rate; HCP NPS post-event (target: >7.5/10)
Secondary KPI
Crossix Rx lift in attendees vs matched non-attendees (industry benchmark: 1.8-2.2x)
Tactic
Pre-brand: 5 anonymous SF3B1+ MDS cases with before/after response data, KOL commentary, peer discussion. At launch: branded case series "SF3B1 Response: What Good Looks Like" with Phase 3 data integration
Timing
T-6mo unbranded → branded at launch (sponsored case series)
HCP Targeting
Hematology + rare disease physician community on Figure1; case-based learning format for community oncologists
Primary KPI
Case views and comment engagement; unique HCP readers
Secondary KPI
Brand recall lift survey in Figure1 hematology cohort
Tactic
Monthly attribution dashboard: which channels drove Rx, cost-per-Rx by channel, HCP decile response rates, rep + digital synergy multiplier. Quarterly reallocation based on Rx-generating vs impression-generating channels
Timing
Launch → ongoing (monthly reporting cycle)
HCP Targeting
Match all digital impressions (Doximity, Medscape, virtual events, web) to Rx activity at the NPI level
Primary KPI
Cost-per-incremental-Rx by channel; channel-level ROAS
Secondary KPI
Rep+digital vs rep-only Rx conversion rate comparison
The oral copay paradox needs its own digital solution. An "MDS Oral Therapy Access Guide" — landing page with SP locator, $0 copay enrollment, and PA appeal toolkit — directly addresses the access friction that kills patient start rates. Make it findable via Google search and linkable by every rep and MSL.
Phase 2 showed 35% diarrhea / 28% nausea in an elderly population. BMS will use this in counter-detailing if you don't address it first. A proactive "Managing GI Events in MDS Oral Therapy" digital resource — clinical tips, dose modification guide, patient support card — neutralizes the objection before the rep encounter.
Community oncologists (Tier 3) are not reading NEJM. They need simple, action-oriented content: "Is [Brand] covered for my patient?" → one-click formulary checker → hub enrollment. The digital experience for community HCPs should be frictionless access, not clinical depth.
SF3B1 mutation testing is the qualifying step for the genetically enriched responder population. A digital "MDS Molecular Testing Pathway" — which labs, which codes, turnaround times — positions the brand as a testing facilitator, builds prescriber habits around molecular testing, and creates a natural brand association before the first prescription.
BMS has a larger field force, deeper formulary relationships, and multi-year prescriber loyalty. They cannot be out-detailed on volume. The opportunity is precision over volume: an NPI-level digital ecosystem that reaches the right 3,000 hematologists with the right message at the exact moment they are diagnosing or treating MDS — and proves it drove prescriptions through closed-loop attribution. That is a structural advantage a 30,000-person franchise cannot replicate regardless of budget.
Seven dimensions weighted by empirical failure frequency from Sedulo Group, McKinsey, and Trinity Life Sciences benchmarking studies. Each dimension's weight reflects how often that factor is cited as a root cause of launch underperformance.
24 diagnostic questions with 4-point graded response scales calibrated to real-world launch outcomes. Scoring normalizes 1-4 responses to 0-100, applies dimension weights, and classifies overall readiness against industry thresholds.
Accordion-based question interface with live Recharts radar visualization and CSS conic-gradient gauge. Pre-populated with a Lower-Risk MDS case study demonstrating the framework's diagnostic power for a pre-commercial launch scenario.